Research Analysts Offer Predictions for Allogene Therapeutics, Inc.’s Q1 2026 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a report issued on Wednesday, September 18th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of ($0.43) for the quarter, up from their prior forecast of ($0.45). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.38) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.80) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%.

A number of other equities research analysts have also recently weighed in on ALLO. Canaccord Genuity Group cut their price objective on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Truist Financial restated a “buy” rating and issued a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Piper Sandler assumed coverage on Allogene Therapeutics in a research report on Friday, May 31st. They set an “overweight” rating and a $11.00 price objective for the company. Citigroup boosted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a report on Thursday, August 15th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Price Performance

NASDAQ:ALLO opened at $2.80 on Monday. Allogene Therapeutics has a 1-year low of $2.01 and a 1-year high of $5.78. The company has a market capitalization of $585.20 million, a PE ratio of -1.56 and a beta of 0.83. The firm’s 50-day moving average price is $2.72 and its 200-day moving average price is $3.01.

Hedge Funds Weigh In On Allogene Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. boosted its holdings in shares of Allogene Therapeutics by 23.1% during the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock valued at $46,000 after acquiring an additional 2,680 shares during the last quarter. Bourgeon Capital Management LLC boosted its holdings in Allogene Therapeutics by 12.8% in the first quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock worth $256,000 after purchasing an additional 6,500 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Allogene Therapeutics by 85.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock worth $79,000 after purchasing an additional 8,162 shares during the period. Nisa Investment Advisors LLC raised its stake in Allogene Therapeutics by 429.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after buying an additional 8,734 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after buying an additional 10,855 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).